Psoriasis Phase III Clinical: Lilly's IL-23 Monoantimizumab is better than Novartis's IL-17A Monotstyx.

Lilly incision () monoantitherapy patients with primary to severe plaque-like psoriasis showed that the drug reached all major and major secondary endpoints in the first week compared to a placeboAnd showing better therapeutic results in the first and last weeks of the experiment than Novartis's mono-resistant () achieved a higher rate of skin removal for all secondary endpoints of the trial, including one yearIncluding cases of moderate to severe plaque psoriasis patients randomly divided into four groups including multiple interval subcutaneous injections followed by weekly injections from the week onwards orThe last group of patients who were given weekly injections from the first week of the week were given a placebo once a weekThe results of the drug efficacy study showed that nearly % of the patients treated reached the primary endpoint of the disease severity improvement and % of the patients reached (psoriasis severity improved at least compared to the baseline)At the same time, more than % of patients in the treatment group reached the end point (overall assessment) and the group was % In addition, the low-dose and high-dose groups of %and % of patients reached the target of % and % respectively in the first week forMonotogenics (also known as) are also currently evaluated in phaseclinical trials of inflammatory bowel disease, including ulcerative colitis and Crohn's disease